UCB: UBS upgrades stock

(CercleFinance.com) - UBS has upgraded its rating on UCB shares from "sell" to "neutral", while raising its target price for them from 88 euros to 105 euros, a new target price that roughly corresponds to the the Belgian pharmaceutical company's latest share price.


2022 EBITDA margin looks better than we previously expected. Bimzelx' US approval looks on track although we think near-term consensus is still too high," the broker summarised.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.